145 related articles for article (PubMed ID: 23425867)
1. Histological features, Ki-67 and Bcl-2 immunohistochemical expression and their correlation with the aggressiveness of pheochromocytomas.
Jovanovic R; Kostadinova-Kunovska S; Bogoeva B; Spasevska L; Petrusevska G
Prilozi; 2012; 33(2):23-40. PubMed ID: 23425867
[TBL] [Abstract][Full Text] [Related]
2. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
3. Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis.
Strong VE; Kennedy T; Al-Ahmadie H; Tang L; Coleman J; Fong Y; Brennan M; Ghossein RA
Surgery; 2008 Jun; 143(6):759-68. PubMed ID: 18549892
[TBL] [Abstract][Full Text] [Related]
4. [Pheochromocytoma--pathohistologic and immunohistochemical aspects].
Tatić S; Havelka M; Paunović I; Bozić V; Diklic A; Brasanac D; Janković R; Jancić-Zguricas M
Srp Arh Celok Lek; 2002 Jul; 130 Suppl 2():7-13. PubMed ID: 12584991
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of the insulin-like growth factor 1 receptor (IGF-1R) is associated with malignancy in familial pheochromocytomas and paragangliomas.
Fernandez MC; Martin A; Venara M; Calcagno Mde L; Sansó G; Quintana S; Chemes HE; Barontini M; Pennisi PA
Clin Endocrinol (Oxf); 2013 Nov; 79(5):623-30. PubMed ID: 23506534
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas.
Guo D; Zhao X; Wang A; Xie Q; Xu X; Sun J
Hum Pathol; 2019 Apr; 86():155-162. PubMed ID: 30594747
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine markers and sustentacular cell count in benign and malignant pheochromocytomas - a comparative study.
Białas M; Okoń K; Dyduch G; Ciesielska-Milian K; Buziak M; Hubalewska-Dydejczyk A; Sobrinho-Simoes M
Pol J Pathol; 2013 Jun; 64(2):129-35. PubMed ID: 23900871
[TBL] [Abstract][Full Text] [Related]
8. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.
Lam KY; Lo CY; Wat NM; Luk JM; Lam KS
J Clin Pathol; 2001 Jun; 54(6):443-8. PubMed ID: 11376017
[TBL] [Abstract][Full Text] [Related]
9. Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.
Kumaki N; Kajiwara H; Kameyama K; DeLellis RA; Asa SL; Osamura RY; Takami H
Endocr Pathol; 2002; 13(2):149-56. PubMed ID: 12165664
[TBL] [Abstract][Full Text] [Related]
10. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
11. [Distinction between benign and malignant pheochromocytomas].
Liu TH; Chen YJ; Wu SF; Gao J; Jiang WJ; Lu ZH; Guan J; Wei SZ; Luo YF; Cao JL; Wan JW
Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):198-202. PubMed ID: 15256107
[TBL] [Abstract][Full Text] [Related]
12. Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors.
Kimura N; Watanabe T; Noshiro T; Shizawa S; Miura Y
Endocr Pathol; 2005; 16(1):23-32. PubMed ID: 16000843
[TBL] [Abstract][Full Text] [Related]
13. [The significance of Ki-67 antigen expression in the distinction between benign and malignant pheochromocytomas].
Feng C; Li HZ; Yan WG; Gao JG; Xu WF; Luo YF; Cao JL
Zhonghua Wai Ke Za Zhi; 2007 Dec; 45(24):1697-700. PubMed ID: 18476530
[TBL] [Abstract][Full Text] [Related]
14. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of Ki67, c-erbB-2, and c-kit antigens in benign and malignant pheochromocytoma.
Tavangar SM; Shojaee A; Moradi Tabriz H; Haghpanah V; Larijani B; Heshmat R; Lashkari A; Azimi S
Pathol Res Pract; 2010 May; 206(5):305-9. PubMed ID: 20189725
[TBL] [Abstract][Full Text] [Related]
16. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
17. Prognostic markers in pheochromocytoma.
Clarke MR; Weyant RJ; Watson CG; Carty SE
Hum Pathol; 1998 May; 29(5):522-6. PubMed ID: 9596278
[TBL] [Abstract][Full Text] [Related]
18. Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N; Takayanagi R; Takizawa N; Itagaki E; Katabami T; Kakoi N; Rakugi H; Ikeda Y; Tanabe A; Nigawara T; Ito S; Kimura I; Naruse M;
Endocr Relat Cancer; 2014 Jun; 21(3):405-14. PubMed ID: 24521857
[TBL] [Abstract][Full Text] [Related]
19. Predicting metastasis of pheochromocytomas using DNA flow cytometry and immunohistochemical markers of cell proliferation: A positive correlation between MIB-1 staining and malignant tumor behavior.
Brown HM; Komorowski RA; Wilson SD; Demeure MJ; Zhu YR
Cancer; 1999 Oct; 86(8):1583-9. PubMed ID: 10526289
[TBL] [Abstract][Full Text] [Related]
20. Pheochromocytomas, PASS, and immunohistochemistry.
Carlsen E; Abdullah Z; Kazmi SM; Kousparos G
Horm Metab Res; 2009 Sep; 41(9):715-9. PubMed ID: 19718615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]